These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15620433)

  • 1. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus.
    Kim YM; Cha BS; Kim DJ; Choi SH; Kim SK; Ahn CW; Lim SK; Kim KR; Huh KB; Lee HC
    Diabetes Res Clin Pract; 2005 Jan; 67(1):43-52. PubMed ID: 15620433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.
    Osei K; Gaillard T; Schuster D
    Metabolism; 2007 Jan; 56(1):24-9. PubMed ID: 17161222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
    Jones TA; Sautter M; Van Gaal LF; Jones NP
    Diabetes Obes Metab; 2003 May; 5(3):163-70. PubMed ID: 12681023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of single nucleotide polymorphism SNP + 45 of the adiponectin gene on the rosiglitazone maleate response in patients with type 2 diabetes].
    Zhang H; Jia WP; Hu C; Zhang R; Wang CR; Bao YQ; Lu JX; Xu J; Xiang KS
    Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2390-3. PubMed ID: 18036314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus.
    Kerenyi Z; Samer H; James R; Yan Y; Stewart M
    Diabetes Res Clin Pract; 2004 Mar; 63(3):213-23. PubMed ID: 14757293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment.
    Kim SK; Hur KY; Kim HJ; Shim WS; Ahn CW; Park SW; Cho YW; Lim SK; Lee HC; Cha BS
    Eur J Endocrinol; 2007 Aug; 157(2):167-74. PubMed ID: 17656594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum transforming growth factor-beta 1 levels in normoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Akan P; Demir T; Bayraktar F; Yesil S
    Hormones (Athens); 2008; 7(1):70-6. PubMed ID: 18359746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
    Patel J; Anderson RJ; Rappaport EB
    Diabetes Obes Metab; 1999 May; 1(3):165-72. PubMed ID: 11220295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.
    Negro R; Mangieri T; Dazzi D; Pezzarossa A; Hassan H
    Diabetes Res Clin Pract; 2005 Oct; 70(1):20-5. PubMed ID: 16126119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
    Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
    Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus.
    Kim HJ; Kim SK; Shim WS; Lee JH; Hur KY; Kang ES; Ahn CW; Lim SK; Lee HC; Cha BS
    Diabetes Res Clin Pract; 2008 Jul; 81(1):42-9. PubMed ID: 18394743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes.
    Yang X; Deng H; Zhang X; Yang D; Yan J; Yao B; Weng J; Xu W
    Sci China Life Sci; 2019 Nov; 62(11):1506-1513. PubMed ID: 31197759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
    Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
    J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.
    Hanefeld M; Patwardhan R; Jones NP;
    Nutr Metab Cardiovasc Dis; 2007 Jan; 17(1):13-23. PubMed ID: 17174222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.